On the contrary, stimulation of the A3 AR by the agonist 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purine-9-yl]-N-methyl-β-D-ribofuranuronamide (IBMECA) has been shown to regulate tumor growth-suppressive mechanisms in melanoma. This evidence concerns the gene ADORA3 and melanoma.